Slide 1: LIFT-AD Topline Readout
LIFT-AD Topline Readout September 3, 2024 Exhibit 99.2
Slide 2: Disclaimer
Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently availab
Slide 3: Therapeutic Potential of HGF Positive Modulation as a Neurotrophic Factor for Neurodegenerative Diseases
3 Therapeutic Potential of HGF Positive Modulation as a Neurotrophic Factor for Neurodegenerative Diseases HGF, hepatocyte growth factor. Potential first-in-class small molecule drug candidates Able to cross the blood-brain barrier Positively modulate HGF/MET Mechanism of action may Reduce inflammat
Slide 4: LIFT-AD Study Design in Mild-to-Moderate Alzheimer's Disease
Randomized, Double-blind, Placebo-controlled, 26-week Trial LIFT-AD Study Design in Mild-to-Moderate Alzheimer’s Disease AChEI, acetylcholinesterase inhibitor; AD, Alzheimer’s disease; ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative St
Slide 5: Baseline Characteristics and Demographics are Well Balanced
Baseline Characteristics and Demographics are Well Balanced © Athira Pharma, Inc. AChEI, acetylcholinesterase inhibitor; ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative Study–Activities of Daily Living; CDR, clinical dementia rating; M
Slide 6: Primary and secondary endpoints did not reach statistical significance
Primary and secondary endpoints did not reach statistical significance Overview of Primary and Secondary Endpoints GST, global statistical test; ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative Study–Activities of Daily Living; NfL, neu
Slide 7: Change in Cognition and Activities of Daily Living
Change in Cognition and Activities of Daily Living ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; ADCS-ADL23, Alzheimer's Disease Cooperative Study–Activities of Daily Living; CFB, change from baseline; LS mean, least squares mean; SE, standard error; SD, standard deviation © A
Slide 8: Fosgonimeton Shows a Neuroprotective Effect Across Plasma Biomarkers
Fosgonimeton Shows a Neuroprotective Effect Across Plasma Biomarkers of Neurodegeneration (NfL), Inflammation (GFAP), and Protein Pathology (Aβ42/40 and p-Tau 217) NfL, neurofilament light chain; GFAP, glial fibrillary acidic protein; Aβ, Amyloid-β; LS mean, least squares mean; SE, standard error *W
Slide 9: Change in Cognition in Mild and Moderate AD by MMSE
Change in Cognition in Mild and Moderate AD by MMSE © Athira Pharma, Inc. ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; MMSE, Mini Mental State Examination; LS mean, least squares mean; SE, standard error Mild Baseline MMSE (20 – 24) Moderate Baseline MMSE (14 – 19) 0 2 6 12 2
Slide 10: Change in Cognition Assessed by ADAS-Cog11 in APOE4 Carriers
Change in Cognition Assessed by ADAS-Cog11 in APOE4 Carriers © Athira Pharma, Inc. ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; MMSE, Mini Mental State Examination; APOE, Apolipoprotein E; LS mean, least squares mean; SE, standard error APOE4 Non-Carrier APOE4 Carrier -1.07 p
Slide 11: Change in Cognition in the Lowest and Highest ADAS-Cog11 Tertile Subsets
Change in Cognition in the Lowest and Highest ADAS-Cog11 Tertile Subsets at Baseline © Athira Pharma, Inc. ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; MMSE, Mini Mental State Examination; LS mean, least squares mean; SE, standard error Lowest Tertile Highest Tertile -2.51 pt
Slide 12: Change in Cognition in CDR Subgroups
Change in Cognition in CDR Subgroups © Athira Pharma, Inc. ADAS-Cog11, Alzheimer's Disease Assessment Scale–Cognitive Subscale; MMSE, Mini Mental State Examination; CDR: Clinical Dementia Rating; LS mean, least squares mean; SE, standard error CDR 1 CDR 2 (moderate AD) -3.74 pts p=0.21 -0.33 pts p=0
Slide 13: Fosgonimeton was generally well tolerated, with a favorable safety profile
Fosgonimeton was generally well tolerated, with a favorable safety profile Summary of Treatment-Emergent Adverse Events (Safety Analysis Population) AE, adverse event; TEAE, treatment-emergent adverse event Most TEAE discontinuations were due to injection site reactions © Athira Pharma, Inc. Subject
Slide 14: Summary and Interpretation
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints; fosgonimeton compares favorably to placebo numerically despite the very small decline in the placebo group In subgroups1 of patients with moderate AD, or APOE4 carriers or those with greatest impairment in cognition by A
Slide 15: Thank You
Thank You © Athira Pharma, Inc.